The Drug Market for Chronic Obstructive Pulmonary Disease Will Increase from Approximately $8.3 Billion in 2010 to More Th

Novel LABA/LAMA Will Drive Market Growth through 2020, According to Findings from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to an expanding aging population, increases in drug treatment and the uptake of premium priced combinations, the drug market for chronic obstructive pulmonary disease (COPD) will increase from approximately $8.3 billion in 2010 to more than $13.4 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The Pharmacor advisory service entitled Chronic Obstructive Pulmonary Disease, which will be published by the end of the month, forecasts that the COPD drug-treated population will expand from approximately 19 million patients in 2010 to nearly 25 million patients in 2020 in the world’s major pharmaceutical markets. Uptake of novel long-acting beta2 agonist/long-acting muscarinic antagonist (LABA/LAMA) fixed-dose combinations, including Boehringer Ingelheim’s olodaterol/tiotropium, will also drive market growth, given that they will likely be more expensive than single-agent bronchodilators.

“The LABA/LAMA combinations will offer more potent bronchodilation than currently available treatments and thought leaders hope that they will also be more effective than currently available treatments in reducing the frequency of COPD exacerbations,” said Decision Resources Analyst Amanda Puffer, M.Sc. “LABA/LAMA combinations will contribute to the erosion of tiotropium sales and are expected to become the sales-leading drug class in COPD by 2020.”

The findings also reveal that the loss of patent protection and/or market exclusivity for many top-selling products will constrain the COPD market. In particular, the two maintenance therapies which dominate the COPD market—Boehringer Ingelheim/Pfizer’s Spiriva and GlaxoSmithKline’s Advair/Seretide/Adoair—together captured 62 percent of the COPD market in 2010 but will capture only 15 percent of the market in 2020 due to generic competition.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Cardiology  Pharmaceutical  General Health

MEDIA:

Logo
 Logo

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.